113 related articles for article (PubMed ID: 19782538)
1. Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections.
Berthoin K; Ampe E; Tulkens PM; Carryn S
Int J Antimicrob Agents; 2009 Dec; 34(6):555-60. PubMed ID: 19782538
[TBL] [Abstract][Full Text] [Related]
2. Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients.
Dailly E; Le Floch R; Deslandes G; Pannier M; Jolliet P
Int J Antimicrob Agents; 2008 Jun; 31(6):537-9. PubMed ID: 18462925
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
Kitzis MD; Goldstein FW
Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis.
Klepser ME; Patel KB; Nicolau DP; Quintiliani R; Nightingale CH
Pharmacotherapy; 1998; 18(5):1069-74. PubMed ID: 9758317
[TBL] [Abstract][Full Text] [Related]
5. Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects.
Ampe E; Delaere B; Hecq JD; Tulkens PM; Glupczynski Y
Int J Antimicrob Agents; 2013 May; 41(5):439-46. PubMed ID: 23523733
[TBL] [Abstract][Full Text] [Related]
6. Variability in teicoplanin protein binding and its prediction using serum albumin concentrations.
Yano R; Nakamura T; Tsukamoto H; Igarashi T; Goto N; Wakiya Y; Masada M
Ther Drug Monit; 2007 Aug; 29(4):399-403. PubMed ID: 17667792
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
[TBL] [Abstract][Full Text] [Related]
8. [Level of evidence for therapeutic drug monitoring of vancomycin].
Jelassi ML; Benlmouden A; Lefeuvre S; Mainardi JL; Billaud EM;
Therapie; 2011; 66(1):29-37. PubMed ID: 21466775
[TBL] [Abstract][Full Text] [Related]
9. Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy.
Covajes C; Scolletta S; Penaccini L; Ocampos-Martinez E; Abdelhadii A; Beumier M; Jacobs F; de Backer D; Vincent JL; Taccone FS
Int J Antimicrob Agents; 2013 Mar; 41(3):261-6. PubMed ID: 23312601
[TBL] [Abstract][Full Text] [Related]
10. A higher dose of vancomycin in continuous infusion is needed in critically ill patients.
Jeurissen A; Sluyts I; Rutsaert R
Int J Antimicrob Agents; 2011 Jan; 37(1):75-7. PubMed ID: 21074374
[TBL] [Abstract][Full Text] [Related]
11. Weight-based loading of vancomycin in patients on hemodialysis.
Brown M; Polisetty R; Gracely EJ; Cuhaci B; Schlecht HP
Clin Infect Dis; 2011 Jul; 53(2):164-6. PubMed ID: 21690623
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin peak serum concentration monitoring.
Tam VH; Moore GE; Triller DM; Briceland LL
J Intraven Nurs; 1999; 22(6):336-42. PubMed ID: 10865602
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin dosage requirements among pediatric intensive care unit patients with normal renal function.
Glover ML; Cole E; Wolfsdorf J
J Crit Care; 2000 Mar; 15(1):1-4. PubMed ID: 10757191
[TBL] [Abstract][Full Text] [Related]
14. Continuous-infusion vancomycin therapy for preterm neonates with suspected or documented Gram-positive infections: a new dosage schedule.
Plan O; Cambonie G; Barbotte E; Meyer P; Devine C; Milesi C; Pidoux O; Badr M; Picaud JC
Arch Dis Child Fetal Neonatal Ed; 2008 Nov; 93(6):F418-21. PubMed ID: 18450803
[TBL] [Abstract][Full Text] [Related]
15. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.
Hermida J; Tutor JC
Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715
[TBL] [Abstract][Full Text] [Related]
16. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.
Hsu DI; Hidayat LK; Quist R; Hindler J; Karlsson A; Yusof A; Wong-Beringer A
Int J Antimicrob Agents; 2008 Nov; 32(5):378-85. PubMed ID: 18701261
[TBL] [Abstract][Full Text] [Related]
17. Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis.
Schaedeli F; Uehlinger DE
Clin Pharmacol Ther; 1998 Jan; 63(1):26-38. PubMed ID: 9465839
[TBL] [Abstract][Full Text] [Related]
18. Using vancomycin concentrations for dosing daptomycin in a morbidly obese patient with renal insufficiency.
Pai MP; Mercier RC; Allen SE
Ann Pharmacother; 2006 Mar; 40(3):553-8. PubMed ID: 16507618
[TBL] [Abstract][Full Text] [Related]
19. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
Lodise TP; Patel N; Lomaestro BM; Rodvold KA; Drusano GL
Clin Infect Dis; 2009 Aug; 49(4):507-14. PubMed ID: 19586413
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and tissue penetration of vancomycin continuous infusion as prophylaxis for vascular surgery.
Payne CJ; Thomson AH; Stearns AT; Watson DG; Zhang T; Kingsmore DB; Byrne DS; Binning AS
J Antimicrob Chemother; 2011 Nov; 66(11):2624-7. PubMed ID: 21840937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
